Tag: targeted therapy
Rb Pathway Inactivation Drives Squamous Transformation in EGFR-Mutant Lung Cancers
A clinicogenomic analysis published in Science Translational Medicine reveals that retinoblastoma pathway inactivation drives squamous transformation in EGFR-mutant lung adenocarcinomas,…
New Drug Shows Promise for Rare Gastrointestinal Tumors in Phase 2 Trial
A phase 2 trial shows rogaratinib, an FGFR inhibitor, demonstrates encouraging efficacy in patients with SDH-deficient GIST. The study represents…
NHS Approves First New Ovarian Cancer Drug in 20 Years for Resistant Disease
NHS approves mirvetuximab soravtansine, the first new ovarian cancer treatment in over 20 years for women with platinum-resistant disease. The…
Breakthrough Drug Targeting ‘Undruggable’ KRAS Mutation Nearly Doubles Pancreatic Cancer Survival
New targeted therapy daraxonrasib successfully inhibits KRAS mutations in pancreatic cancer, nearly doubling survival times. Clinical trial shows 60% reduction…
Breakthrough Drug Shows 75% Response Rate in Hard-to-Treat Lung Cancer
Sunvozertinib achieved a 75% response rate in previously untreated lung cancer patients with EGFR exon 20 mutations, compared to 25%…
New Drug Daraxonrasib Nearly Doubles Pancreatic Cancer Survival in Phase 3 Trial
Daraxonrasib nearly doubles survival in advanced pancreatic cancer patients with KRAS G12C mutations. The breakthrough targets a previously "undruggable" protein…
New Pancreatic Cancer Drug Daraxonrasib Shows Promise in Phase 2 Trial
A phase 2 trial published in NEJM shows promise for daraxonrasib, a novel targeted therapy for previously treated metastatic pancreatic…
Savolitinib Shows Promise for MET-Amplified Gastric Cancer in Phase 2 Trial
A phase 2 trial shows promising clinical efficacy for savolitinib in treating patients with MET-amplified gastric or gastroesophageal junction adenocarcinoma.…